CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7044 result(s)

onasemnogene abeparvovec (Zolgensma)

Last Updated: November 18, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: onasemnogene abeparvovec
Indications: ​Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: Initial

ravulizumab (TBC)

Last Updated: November 19, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ravulizumab
Indications: ​For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.

  • Brand Name: TBC
  • Manufacturer: Alexion Pharma Canada Corp
  • Project Number: SR0623-000
  • Project Status: Withdrawn
  • Submission Type: Initial

encorafenib (Braftovi)

Last Updated: November 20, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: encorafenib
Indications: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy.

  • Brand Name: Braftovi
  • Manufacturer: Pfizer Canada ULC
  • Project Number: PC0233-000
  • Project Status: Pending
  • Submission Type: Initial

amifampridine (Ruzurgi)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: amifampridine
Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

  • Brand Name: Ruzurgi
  • Manufacturer: Médunik Canada Inc.
  • Project Number: SR0660-000
  • Project Status: Active
  • Submission Type: Initial

budesonide (Jorveza )

Last Updated: November 20, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial